| |
Alternative Name : | Mouse monoclonal to Actemra |
Immunogen Information : | Tocilizumab |
Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration. It has a high affinity to IL-6R and blocks the IL-6 signaling by preventing the formation of the IL-6/IL-6R complex. Tocilizumab is used for the trea™ent of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Anti-Tocilizumab Antibody (6C10), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Tocilizumab.
Reconstitute Lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration range is a recommended starting point for this product.
ELISA detection: 0.01-0.1 µg/ml
ELISA blocking: 1-30 µg/ml
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews |